- Public Comps
- Kweichow Moutai
Kweichow Moutai Valuation Multiples
Discover Kweichow Moutai's revenue and EBITDA valuation multiples and investment history, alongside public comparables like LVMH, AB InBev, Heineken, Ambev and more.
Kweichow Moutai Overview
About Kweichow Moutai
Kweichow Moutai is one of China's leading liquor producers. The company was established in 1951 and its headquarters are located in Moutai Town, Guizhou province, southwest China. Its flagship product, 53-degree Feitian Moutai, is known as China's national drink and has been consumed during many high-profile historical and political events. Given its remarkable pricing power, premium product quality, and unparalleled brand strength, the company achieves the industry's highest retail prices and profit margins. The state-owned Assets Supervision and Administration Commission of Guizhou province through Moutai Group controls a 49% stake in Kweichow Moutai.
Founded
1999
HQ

Employees
34.8K
Website
Sectors
Financials (LTM)
EV
$215B
Valuation Multiples
Start free trialKweichow Moutai Financials
Kweichow Moutai reported last 12-month revenue of $26B and EBITDA of $17B.
In the same LTM period, Kweichow Moutai generated $24B in gross profit, $17B in EBITDA, and $12B in net income.
Revenue (LTM)
Kweichow Moutai P&L
In the most recent fiscal year, Kweichow Moutai reported revenue of $25B and EBITDA of $17B.
Kweichow Moutai is profitable as of last fiscal year, with gross margin of 91%, EBITDA margin of 68%, and net margin of 48%.
Financial data powered by Morningstar, Inc.
Kweichow Moutai Stock Performance
Kweichow Moutai has current market cap of $222B, and enterprise value of $215B.
Market Cap Evolution
Kweichow Moutai's stock price is $177.41.
Kweichow Moutai share price increased by 1.7% in the last 30 days, and decreased by 14.1% in the last year.
Kweichow Moutai has an EPS (earnings per share) of $9.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $215B | $222B | 2.1% | 1.7% | -12.4% | -14.1% | $9.70 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKweichow Moutai Valuation Multiples
Kweichow Moutai trades at 8.3x EV/Revenue multiple, and 12.4x EV/EBITDA.
EV / Revenue (LTM)
Kweichow Moutai Financial Valuation Multiples
As of July 11, 2026, Kweichow Moutai has market cap of $222B and EV of $215B.
Kweichow Moutai has a P/E ratio of 17.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kweichow Moutai Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Kweichow Moutai Margins & Growth Rates
Kweichow Moutai grew revenue by 5% and EBITDA by 3% in the last fiscal year.
In the most recent fiscal year, Kweichow Moutai reported gross margin of 91%, EBITDA margin of 68%, and net margin of 48%.
Kweichow Moutai Margins
Kweichow Moutai Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Kweichow Moutai Operational KPIs
Kweichow Moutai's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Kweichow Moutai's Rule of 40 is 72% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kweichow Moutai's Rule of X is 79% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Kweichow Moutai Competitors
Kweichow Moutai competitors include LVMH, AB InBev, Heineken, Ambev, Diageo, Wuliangye, Backus, Constellation Brands and Heineken Holding.
Most Kweichow Moutai public comparables operate across Alcohol.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.2x | 3.2x | 10.3x | 10.9x | |||
| 3.6x | 3.4x | 10.1x | 9.6x | |||
| 1.9x | 1.9x | 8.5x | 8.2x | |||
| 2.5x | 2.5x | 7.8x | 7.5x | |||
| 3.3x | 3.4x | 9.6x | 10.4x | |||
| 4.0x | 3.4x | 12.1x | 9.8x | |||
| - | - | - | - | |||
This data is available for Pro users. Sign up to see all Kweichow Moutai competitors and their valuation data. Start Free Trial | ||||||
Investments by Kweichow Moutai
Kweichow Moutai has invested in 4 companies to date.
Latest investment by Kweichow Moutai was on June 28th 2026. Kweichow Moutai invested in AI² Robotics in their $739M Series C round (EV/Revenue multiple available to Pro users).
Latest Investments by Kweichow Moutai
| Description | AI² Robotics is a developer of embodied intelligent robots for general-purpose tasks. Shanghai-headquartered, it produces humanoid terminals with vision-language models for warehouse picking and elderly care. The robots navigate dynamic environments using LiDAR and 7-axis arms. AI² Robotics deploys fleets in 50 factories across China, integrating with ROS frameworks. Founded in 2022, it collaborates with Baidu on multimodal perception. | Zhishen Technology is a specialist in embodied intelligence, developing technologies for physical AI interactions. | Jize Biotech is a Shanghai-headquartered biotechnology firm specializing in the development and commercialization of synthetic bear bile powder as an ethical alternative to traditional sources. It advances sustainable biomedical products through rigorous research, standardized manufacturing, and innovative processes. | Shanghai-based Synaura is a biotechnology company producing human milk oligosaccharides through biosynthesis for infant formula additives. Its HMOs replicate structures found in breast milk, supporting immune development and gut health in formula-fed babies. |
| HQ Country | ||||
| HQ City | Beijing | - | - | Shanghai |
| Deal Date | 28 Jun 2026 | 21 Mar 2026 | 4 Dec 2025 | 9 May 2024 |
| Round | Series C | Series B | Series A | Seed |
| Raised | $739M | undisclosed | undisclosed | $14M |
| Investors | GSR United Capital; China Bester Group; Sino Biopharmaceutical; Dunhong Capital Management; Hongtai Capital Holdings; Baidu Capital; Kweichow Moutai; Shenzhen Capital Group; Liangxi Venture Capital; Pharmaron Beijing; Guangdong Yuecai Venture Capital Co., Ltd.; Zhejiang XCC Group | Kweichow Moutai | Fujian Guoli Minsheng; Kweichow Moutai | CICC Qide; China Mengniu Dairy; Kweichow Moutai; Zhongjin Qide |
| Valuation | $3B | undisclosed | undisclosed | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Kweichow Moutai investments and their VC round multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kweichow Moutai
| When was Kweichow Moutai founded? | Kweichow Moutai was founded in 1999. |
| Where is Kweichow Moutai headquartered? | Kweichow Moutai is headquartered in China. |
| How many employees does Kweichow Moutai have? | As of today, Kweichow Moutai has over 34K employees. |
| Is Kweichow Moutai publicly listed? | Yes, Kweichow Moutai is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Kweichow Moutai? | Kweichow Moutai trades under 600519 ticker. |
| When did Kweichow Moutai go public? | Kweichow Moutai went public in 2001. |
| Who are competitors of Kweichow Moutai? | Kweichow Moutai main competitors include LVMH, AB InBev, Heineken, Ambev, Diageo, Wuliangye, Backus, Constellation Brands, Heineken Holding. |
| What is the current market cap of Kweichow Moutai? | Kweichow Moutai's current market cap is $222B. |
| What is the current revenue of Kweichow Moutai? | Kweichow Moutai's last 12 months revenue is $26B. |
| What is the current revenue growth of Kweichow Moutai? | Kweichow Moutai revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Kweichow Moutai? | Current revenue multiple of Kweichow Moutai is 8.3x. |
| What is the current EBITDA of Kweichow Moutai? | Kweichow Moutai's last 12 months EBITDA is $17B. |
| What is Kweichow Moutai's EBITDA margin? | Kweichow Moutai's last 12 months EBITDA margin is 67%. |
| What is the current EV/EBITDA multiple of Kweichow Moutai? | Current EBITDA multiple of Kweichow Moutai is 12.4x. |
| What is the current FCF of Kweichow Moutai? | Kweichow Moutai's last 12 months FCF is $10B. |
| What is Kweichow Moutai's FCF margin? | Kweichow Moutai's last 12 months FCF margin is 40%. |
| What is the current EV/FCF multiple of Kweichow Moutai? | Current FCF multiple of Kweichow Moutai is 20.5x. |
| How many companies Kweichow Moutai has acquired to date? | Kweichow Moutai hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Kweichow Moutai has invested to date? | As of July 2026, Kweichow Moutai has invested in 4 companies. |
| What was the last Kweichow Moutai investment? | On 28th June 2026 Kweichow Moutai invested in AI² Robotics, participating in a $739M Series C round at $3B valuation, alongside GSR United Capital, China Bester Group, Sino Biopharmaceutical, Dunhong Capital Management, Hongtai Capital Holdings, Baidu Capital, Shenzhen Capital Group, Liangxi Venture Capital, Pharmaron Beijing, Guangdong Yuecai Venture Capital Co., Ltd., and 1 other investor. |
| In what companies Kweichow Moutai invested in? | Kweichow Moutai invested in AI² Robotics, Synaura, Zhishen Technology, and Jize Biotech. |
See public comps similar to Kweichow Moutai
Lists including Kweichow Moutai
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





